Full-Time

Lifecycle Leader

Ophthalmology

Posted on 9/27/2025

Deadline 10/18/25
Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

San Bruno, CA, USA

Hybrid

The job may require in-office presence in either Basel or South San Francisco.

Category
Medical, Clinical & Veterinary (1)
Required Skills
Marketing
Requirements
  • Significant experience of marketing with a commercial & scientific understanding of with an established network of external stakeholders. Late Stage Development experience would be preferable
  • Prior experience with Ophthalmic diseases, with a preference for Retinal diseases
  • Outstanding leadership skills: proven track record in building agile teams and ability to influence in a collaborative way within a cross functional environment
  • Exceptional strategic orientation and agility: outstanding ability to develop long term vision and deep understanding of the global pharmaceutical/biotechnology industry to create robust and innovative business strategies
  • Demonstrable previous accomplishments should include developing and overseeing the execution of breakthrough development and/or commercial strategies that have led to competitive results and increased the long-term, sustainable success of multiple products
  • Proven abilities to work effectively in a complex, matrix environment, across functions and departments
  • Extensive experience in launch planning and management, deep understanding of global health systems and access/reimbursement challenges, and product life-cycle planning and management
  • Strong leadership experience in global marketing in the areas of Life-cycle management, Disease Area management, Country Management, Commercial and Global Medical Affairs or related disciplines (such as Lifecycle Leader, Senior Disease Area Director, Global Medical Director or related disciplines)
  • Proven track record for consistently meeting or exceeding ambitious financial and/or other quantitative targets, as well as qualitative goals, for large departments/teams in the pharmaceutical, biotechnology or related industry
  • Strong communication and presentation skills at c-suite level and ability to perform under pressure
Responsibilities
  • You manage a product within the Ophthalmology portfolio as the single person accountable for the global strategy, budget requirements, resource allocation and its successful implementation towards financial targets
  • You will lead the cross functional LCT for a product within the Ophthalmology portfolio, deciding team composition and tenure of membership based on agile principles and ensuring fit for purpose resourcing
  • You will work closely within a triad with the Global Development Leader (GDL) and the Commercial Strategy Leader (CSL) for the global development and commercialization strategy; and linked to the context of disease level strategies as applicable
  • You will link the LCT to their external network and ensure an outside-in approach to decision making
  • You maintain and nurture a culture of transparency, collaboration (across functions) and trust
  • You will be a contributing member of the Ophthalmology TA leadership team
  • You shape the long term vision and strategy E2E across the value chain in partnership with REDs, PD, Partnering, GPS and PDMA and PI leads to delivering more innovation at lower cost to society
  • You support licensing and other business development activities and partner with GPS, pRED & gRED (Roche / Genentech, Research and Early Development), and (PD) Product Development
  • You influence molecule optimization within and across the Disease Area plus relevant therapeutic areas ensuring consideration is given to critical decisions which could impact value capture
  • You serve as a thought partner and sounding board for the GPS Teams within this Franchise and various internal partners/stakeholders; ensuring franchise goals are met
  • You inspire and aligning people towards a vision while building a culture of accountability, collaboration, diversity, inclusion and trust
  • You act from a whole system perspective, displaying an enterprise portfolio mindset and understanding the big picture of how the organization’s mission fits in the marketplace
  • You act with a sense of urgency and curiosity, take smart risks; embody a competitive & an entrepreneurial growth mindset to reach beyond boundaries, and experiments with the right balance between long term and short term outcomes
  • You role model our ways of working, mindset and behaviors in practice (VACC - Visionary, Architect, Catalyst, Coach, experimentation, learning fast, collaboration, servant leadership)
  • You are accountable to maximize the life-cycle value to patients, society and Roche through leading the global cross-functional molecule strategy from late stage development, manufacturing, commercialization, budget requirements and its successful implementation
  • You will lead a matrix team and will collaborate with functional leaders to shape team composition, membership and selection based on the needs of your program
  • You will make decisions for the molecule/s across all functions and are the single decision-maker while empowering cross functional sub-team leaders. You are accountable to ensure appropriate internal and external advice needed for decisions. You are a standing member of the respective Disease Area Team(s) and you will design molecule strategies in the context of disease level strategies where applicable
  • You will act with a portfolio view across the Ophthalmology franchise as well as wider enterprise; ensuring clarity and appropriate trade-off
Desired Qualifications
  • Late Stage Development experience would be preferable
  • Preference for Retinal diseases

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Simplify Jobs

Simplify's Take

What believers are saying

  • PathAI acquisition for $750M in 2026 scales AI-driven digital pathology globally.
  • C4 Therapeutics DAC partnership yields up to $1B in next-gen cancer therapies.
  • CT-388 weight-loss drug targets double-digit share against Novo Nordisk, Eli Lilly.

What critics are saying

  • Swiss franc appreciation erodes 70% international revenue immediately.
  • Avastin, Herceptin patents expire 2028, Amgen biosimilars capture 50% share.
  • Tempus-Epic AI pathology platform steals 30% deals from PathAI by Q3 2026.

What makes Roche unique

  • Pioneered mass production of synthetic vitamin C in 1934 as Redoxon.
  • Acquired Genentech majority stake in 1990, entering biotechnology leadership.
  • Secured PCR technology rights from Cetus in 1991 for diagnostics dominance.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.

INACTIVE